Goldman initiates coverage on Intuitive Surgical with a buy rating because robot-assisted procedures will double in the next two years.
*AstraZeneca sets durvalumab price at $15,000/ month. Leerink analyst Seamus Fernandez sees durvalumab capturing a modest 10 percent of the estimated $2.3 billion global bladder cancer market, while AstraZeneca in 2014 put the drug's peak sales in all cancers at $6.5 billion, including combination use. The U.S. Food and Drug Administration said late on Monday...
*AstraZeneca sets durvalumab price at $15,000/ month. May 1- U.S. regulators have approved AstraZeneca's key immunotherapy drug durvalumab as a treatment for bladder cancer, marking the first commercial green light for a product the company hopes will go on to sell billions of dollars. The U.S. Food and Drug Administration said on Monday it granted accelerated...
May 1- The U.S. Food and Drug Administration on Monday granted accelerated approval to AstraZeneca Plc's immuno-oncology drug to treat a type of bladder cancer in patients whose disease progressed despite chemotherapy. The FDA also approved a complementary diagnostic from Roche Holding AG to assess whether the PD-L1 protein is expressed in urothelial...
NBC news reports that a compound found in the protective slime of an Indian frog might become a powerful new drug to treat the flu, according to research.
"Huge shocks from the political system are always a distraction," athenahealth's Jonathan Bush told CNBC.
Owlet is out with Smart Sock 2, an updated version of the original, that seamlessly monitors your baby's breathing and vitals after leaving the hospital in the comfort of your home.
Jim Cramer sees a hidden bull market in the fast-growing dental industry.
Former Aetna CEO Ron Williams weighs in on what changes could be ahead for the Affordable Care Act and consumers.
To expand its brand and products, Peloton is installing its first president.
As many as 6 million Americans have atrial fibrillation, the most common form of cardiac arrhythmia. It’s caused when the electrical signaling that keeps our hearts beating becomes erratic, and, in its most serious forms, can lead to stroke or heart failure.
Bloomlife has developed a sensor to help eliminate anxiety for pregnant women in their third trimester.
TipRanks presents the top 10 stock ideas for next year from the five best-performing health-care analysts of 2016.
CNBC's Landon Dowdy looks into the cybersecurity of medical devices.
James Dinan, York Capital Management founder and CEO, shares his top stock picks, including St. Jude and Monsanto.
St. Jude has issued warnings about 400,000 of its heart defibrillators after two people died from malfunctions, NBC News reports.
Theranos and its founder Elizabeth Holmes have been sued by one of the blood-testing start-up's biggest backers, according to a WSJ report.
CNBC's Meg Tirrell reports the latest details surrounding Johnson & Johnson and the cyber hack of one of the company's medical devices. Jay Radcliffe, Rapid7 senior security consultant, weighs in.
St. Jude reopens, with fractionally higher stocks, CNBC's Bob Pisani reports.
Check out the companies making headlines after the bell Tuesday.